Every week, Molecular Imaging brings hard-hitting neuroimaging research to light, but today we are highlighting the unorthodox work of one neuroscientist—his paintings, in fact, which depict the microstructure of the brain.

Definiens, the global leader in Tissue Phenomics® for oncology diagnostics, today announced the newest version of its leading image analysis software for quantitative digital pathology, Tissue Studio 4.0. The new release provides greater flexibility, more accurate and consistent results, and the ability to use any chromogen for single and dual stain immunohistochemistry (IHC) quantification.

Genetic research from John Hopkins and the University of Alabama Birmingham are providing a road map of inflammation linked to autism thanks to a fleet of tissue samples from 72 autistic and healthy brains. Analyses of these tissues showed microglial cells in perpetual hyperdrive, which translates into neuro-inflammation.

Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that it has reached the planned enrollment of 1,200 patients in the PROSPECT Phase 3 clinical study of its targeted active immunotherapy candidate, PROSTVAC®, in the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Patients were enrolled at 214 sites in 15 countries.

One of the biggest challenges in medicine today is getting effective diagnostic and therapeutic drugs through the regulatory process unscathed. Judit Rius, the U.S. manager and legal policy adviser for Doctors Without Borders has words of wisdom to share about how to improve FDA reviews and incentives for the development of treatments for much needed drugs, including those for neglected tropical diseases.

NeuroLaunch, the first major worldwide program for neuroscience technology businesses, is taking Atlanta by storm in a rolling 90-day program aimed to give participants and their companies the tools needed to succeed, including seed funding, mentorship, and other resources, such as access to top research centers.

Cambridge, Mass., based biomedical company Biogen Idec announced encouraging results of a phase II drug targeting amyloid in Alzheimer’s patients at a Deutsche Bank conference in Boston today.

Royal Philips, a leader in image-guided therapies, announced that it has signed an agreement with Image Stream Medical (ISM) that allows Philips to further expand its integration solutions for its hybrid suite and interventional lab solutions with integrated video and live streaming capabilities. As part of the agreement, Philips has acquired a minority stake in ISM. Financial terms of the agreement were not disclosed.